SCHEMBL30559792

SCHEMBL30559792

O=C(Nc1ccccc1)Nc1ccc(Nc2cc(-n3ccnc3)ncn2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 1/20 0.57
▸ BCR P11274 1/20 0.57
▸ MAPT P10636 2/20 0.52
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ CASP3 P42574 1/20 0.46
▸ SENP7 Q9BQF6 1/20 0.46
▸ KDR P35968 3/20 0.45
▸ NAMPT P43490 1/20 0.45
▸ CYP1A2 P05177 4/20 0.44
▸ CYP3A4 P08684 4/20 0.44
▸ CYP2D6 P10635 4/20 0.44
▸ CYP2C19 P33261 3/20 0.44
▸ HSD17B10 Q99714 3/20 0.44
▸ CLK4 Q9HAZ1 3/20 0.44
▸ ALOX15 P16050 2/20 0.44
▸ TSHR P16473 2/20 0.44
▸ CCNT1 O60563 1/20 0.44
▸ CCNE1 P24864 1/20 0.44
▸ CDK2 P24941 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21570550 0.88 ABL1 (0.57) ABL1BCRMAPTMEN1KMT2A
SCHEMBL15436240 0.77 EGFR (0.62) MEN1KMT2ACASP3SENP7KDR
SCHEMBL6402301 0.73 ABL1 (1.00) ABL1BCRCCNT1CCNE1CDK2
SCHEMBL11541657 0.71 MEN1 (0.76) MAPTMEN1KMT2ACASP3SENP7
SCHEMBL1897213 0.71 KDR (0.80) KDRTNNI3K
SCHEMBL13472422 0.69 CYP1A2 (0.50) ABL1BCRMAPTCYP1A2CYP3A4
SCHEMBL9521235 0.68 CYP3A4 (0.58) ABL1BCRMAPTCYP1A2CYP3A4
SCHEMBL1518723 0.68 CNR1 (0.69) CASP3SENP7CLK4TSHRCDK9
SCHEMBL374604 0.68 MEN1 (0.66) MAPTMEN1KMT2AKDRLMNA
SCHEMBL25825682 0.68 TAAR1 (0.85) MAPTMEN1KMT2ACASP3SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3784650-B1 N-PHENYL-N'-(4-{[6-(1H-IMIDAZOL-1-YL)-4-PYRIMIDINYL]AMINO}PHENYL)UREA DERIVATIVES AS MCT4 INHIBITORS FOR THE TREATMENT OF CANCER CHARLES R DREW UNIV OF MEDICINE AND SCIENCE (US) 2023-09-06 — — EP disclosed
EP-3784650-C0 N-PHENYL-N'-(4-{[6-(1H-IMIDAZOL-1-YL)-4-PYRIMIDINYL]AMINO}PHENYL)UREA DERIVATIVES AS MCT4 INHIBITORS FOR THE TREATMENT OF CANCER CHARLES R DREW UNIV OF MEDICINE AND SCIENCE (US) 2023-09-06 — — EP disclosed
Send feedback